This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


trusted source


Sotagliflozin found to protect kidney and heart in patients with type 2 diabetes and chronic kidney disease

Credit: Pixabay/CC0 Public Domain

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, which are medications that lower blood sugar levels among other effects, provide kidney- and heart-related benefits to patients with and without diabetes. An exploratory analysis recently uncovered the effects of sotagliflozin, a dual SGLT1 and 2 inhibitor, in patients with type 2 diabetes and chronic kidney disease. The research will be presented at ASN Kidney Week 2023 November 1–5.

The analysis involved data from the SCORED trial, a phase 3, double-blind, placebo-controlled study that randomized 10,584 patients with type 2 diabetes, , and cardiovascular factors to receive sotagliflozin or placebo. The outcomes assessed included kidney and cardiorenal composites derived using laboratory values.

Over a median follow-up of 16 months, 223 events were identified, and sotagliflozin reduced the risk of the composite of sustained ≥50% decline in estimated , estimated glomerular filtration rate <15 mL/min/1.73m2, dialysis, or kidney transplant by 38%. Sotagliflozin also reduced the risk of a cardiorenal composite outcome (the above composite plus cardiovascular- or kidney-related death) by 23%.

"These effects are consistent with what has been reported with other SGLT in people with type 2 diabetes at high cardiorenal risk and add to the already reported benefits of sotagliflozin in reducing both heart failure and ischemic events such as myocardial infarction or stroke," said corresponding author David Cherney, MD CM, Ph.D., FRCP(C), of the University of Toronto.

"Sotagliflozin is now FDA approved under the name 'INPEFA' to reduce the risk of cardiovascular death and heart failure events with a broad label that includes patients with heart failure or chronic disease, so the drug is now an option for nephrologists and cardiologists, as well as primary care physicians, to prescribe."

More information: Study: Sotagliflozin and Kidney and Cardiorenal Outcomes in SCORED

Citation: Sotagliflozin found to protect kidney and heart in patients with type 2 diabetes and chronic kidney disease (2023, November 3) retrieved 24 June 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Medicine trial meets primary endpoint in patients with chronic kidney disease


Feedback to editors